Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inhibrx Biosciences Inc (INBX)
NASDAQ:INBX
Holding INBX?
Track your performance easily
INBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.80 - $18.95
Previous CloseN/A
Volume23.61K
Average Volume (3M)82.03K
Market Cap
$190.36M
Enterprise Value$32.20M
Total Cash (Recent Filing)$128.66M
Total Debt (Recent Filing)$35.95M
Price to Earnings (P/E)―
Beta1.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding14,475,904
10 Day Avg. Volume102,140
30 Day Avg. Volume82,027
Standard Deviation0.25
R-Squared0.23
Alpha-0.00176
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)129.67
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.17
Enterprise Value/Revenue18.37
Enterprise Value/Gross Profit19.70
Enterprise Value/Ebitda-0.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Inhibrx Biosciences Inc News
PremiumCompany Announcements
Inhibrx Biosciences Reports Promising Trial Results for INBRX-109PremiumCompany Announcements
Inhibrx Biosciences Secures $150M Loan for GrowthPremiumCompany Announcements
Inhibrx Biosciences Reveals Updated Corporate Presentation
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyINBRX-106 showed promising results with a 50% ORR in HNSCC patients, including 2 complete responses.
Clinical TrialsOzekibart's registrational path in chondrosarcoma is progressing with enrollment of the Phase 2 pivotal trial, with the FDA giving the green light for a registrational study.
Financial PerformanceInhibrx is well capitalized with $196.3MM in cash to continue developing its key treatments.
Bears Say
Financial PerformanceInhibrx reported no revenues for 3Q24.
Safety ConcernsThe safety profile may limit the use of the combination treatment due to the potential for severe side effects.
ValuationMarket Perform rating is based on the expected cash position at 1Q25E of $77MM/14.6MM shares outstanding, resulting in a value of $5.27.
---
Ownership Overview
27.36% Insiders
6.17% Mutual Funds
<0.01% Other Institutional Investors
58.32% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INBX FAQ
What was Inhibrx Biosciences Inc’s price range in the past 12 months?
Inhibrx Biosciences Inc lowest stock price was $10.80 and its highest was $18.95 in the past 12 months.
What is Inhibrx Biosciences Inc’s market cap?
Inhibrx Biosciences Inc’s market cap is $190.36M.
When is Inhibrx Biosciences Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Inhibrx Biosciences Inc’s earnings last quarter?
Inhibrx Biosciences Inc released its earnings results on Aug 13, 2024. The company reported $125.48 earnings per share for the quarter, beating the consensus estimate of -$3.6 by $129.08.
Is Inhibrx Biosciences Inc overvalued?
According to Wall Street analysts Inhibrx Biosciences Inc’s price is currently Overvalued.
Does Inhibrx Biosciences Inc pay dividends?
Inhibrx Biosciences Inc does not currently pay dividends.
What is Inhibrx Biosciences Inc’s EPS estimate?
Inhibrx Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inhibrx Biosciences Inc have?
Inhibrx Biosciences Inc has 14,475,904 shares outstanding.
What happened to Inhibrx Biosciences Inc’s price movement after its last earnings report?
Inhibrx Biosciences Inc reported an EPS of $125.48 in its last earnings report, beating expectations of -$3.6. Following the earnings report the stock price went down -3.489%.
Which hedge fund is a major shareholder of Inhibrx Biosciences Inc?
Currently, no hedge funds are holding shares in INBX
---
Inhibrx Biosciences Inc Stock Smart Score
Company Description
Inhibrx Biosciences Inc
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
---
Technical Analysis
---